150 related articles for article (PubMed ID: 2863809)
1. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
Chiu P; Rajakumar G; Chiu S; Johnson RL; Mishra RK
Peptides; 1985; 6(2):179-83. PubMed ID: 2863809
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
[TBL] [Abstract][Full Text] [Related]
3. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
Chiu S; Paulose CS; Mishra RK
Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
[TBL] [Abstract][Full Text] [Related]
4. Modulation of CNS dopamine receptors by peptides.
Mishra RK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):437-42. PubMed ID: 6141599
[TBL] [Abstract][Full Text] [Related]
5. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats.
Bhargava HN
Neuropharmacology; 1984 Apr; 23(4):439-44. PubMed ID: 6145116
[TBL] [Abstract][Full Text] [Related]
6. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
Chiu S; Paulose CS; Mishra RK
Peptides; 1981; 2(1):105-11. PubMed ID: 6113579
[TBL] [Abstract][Full Text] [Related]
7. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
[TBL] [Abstract][Full Text] [Related]
8. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
Srivastava LK; Bajwa SB; Johnson RL; Mishra RK
J Neurochem; 1988 Mar; 50(3):960-8. PubMed ID: 2892892
[TBL] [Abstract][Full Text] [Related]
9. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
Bhargava HN
Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.
Kostrzewa RM; Saleh MI
Neuropharmacology; 1989 Aug; 28(8):805-10. PubMed ID: 2571103
[TBL] [Abstract][Full Text] [Related]
11. Differences in the time course of haloperidol-induced up-regulation of rat striatal and mesolimbic dopamine receptors.
Prosser ES; Csernansky JG; Hollister LE
Life Sci; 1988; 43(8):715-20. PubMed ID: 2901023
[TBL] [Abstract][Full Text] [Related]
12. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny.
Saleh MI; Kostrzewa RM
Peptides; 1989; 10(1):35-9. PubMed ID: 2568624
[TBL] [Abstract][Full Text] [Related]
13. CNS dopamine receptors: effect of prolyl-leucyl-glycinamide and solubilization.
Mishra RK
Nutr Health; 1984; 3(3):175-87. PubMed ID: 6152723
[TBL] [Abstract][Full Text] [Related]
14. Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density.
Prasad C; Spahn SA; Ikegami H
Biochem Biophys Res Commun; 1989 Feb; 159(1):48-52. PubMed ID: 2522303
[TBL] [Abstract][Full Text] [Related]
15. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.
Prosser ES; Pruthi R; Csernansky JG
Psychopharmacology (Berl); 1989; 99(1):109-16. PubMed ID: 2506596
[TBL] [Abstract][Full Text] [Related]
16. MIF-I and postsynaptic receptor sites for dopamine.
Kostrzewa RM; Hardin JC; Snell RL; Kastin AJ; Coy DH; Bymaster F
Brain Res Bull; 1979; 4(5):657-62. PubMed ID: 39665
[TBL] [Abstract][Full Text] [Related]
17. L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.
Ott MC; Costain WJ; Mishra RK; Johnson RL
Peptides; 2000 Feb; 21(2):301-8. PubMed ID: 10764960
[TBL] [Abstract][Full Text] [Related]
18. The effect of chronic L-dopa administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain.
Reches A; Wagner HR; Jiang D; Jackson V; Fahn S
Life Sci; 1982 Jul; 31(1):37-44. PubMed ID: 7109853
[TBL] [Abstract][Full Text] [Related]
19. Striatal dopamine receptor function in morphine-tolerant dependent rats: influence of hypothalamic peptides.
Bhargava HN
NIDA Res Monogr; 1984 Mar; 49():320-6. PubMed ID: 6148693
[No Abstract] [Full Text] [Related]
20. Striatal dopamine receptor supersensitivity after long-term haloperidol treatment of hypophysectomized rats.
DeLucia R; Scavone C; Camillo MA
Braz J Med Biol Res; 1989; 22(6):741-3. PubMed ID: 2620186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
